Muhm M, Kalhs P, Sunder-Plassmann G, Apsner R, Brugger S, Druml W
Department of Cardiothoracic/Vascular Anesthesia, University of Vienna, Austria.
Anesth Analg. 1997 Jan;84(1):80-4. doi: 10.1097/00000539-199701000-00015.
Long-term central venous lines for chronic hemoaccess are usually inserted in the operating theater under local or general anesthesia or in interventional radiology suites using fluoroscopic technique. In a prospective study we determined the feasibility of percutaneous insertion of Hickman catheters without fluoroscopic control by anesthesiologists and intensivists in the setting of an intensive care unit. Fifty-four Hickman catheters were placed in 53 consecutive patients with hematological disorders and/or neoplastic diseases undergoing allogeneic or autologous bone marrow transplantation (BMT) or buffy coat therapy. There were no major complications. The mean time for insertion was 35 min. The median life span of catheters was 70 days (range 3-214). Twenty-six catheters were electively removed; six remained functioning in situ at the end of the study. For 3333 catheter days (1471 days in hospital and 1862 days at domiciliary care), six catheters were removed because of mechanical complications (inadvertent dislodgement, leak, secondary migration) and 14 because of suspected or documented infection. We conclude that percutaneous nonangiographic insertion of Hickman catheters by anesthesiologists minimizes technical expenditure and is at least as effective as surgical or radiological techniques. The rate of clinically important complications is acceptable.
用于慢性血液通路的长期中心静脉导管通常在手术室在局部或全身麻醉下插入,或在介入放射科套房使用荧光透视技术插入。在一项前瞻性研究中,我们确定了麻醉医生和重症监护医生在重症监护病房环境中在无荧光透视控制的情况下经皮插入Hickman导管的可行性。对53例连续接受异基因或自体骨髓移植(BMT)或白膜层治疗的血液系统疾病和/或肿瘤性疾病患者放置了54根Hickman导管。未发生重大并发症。插入的平均时间为35分钟。导管的中位寿命为70天(范围3 - 214天)。26根导管被选择性拔除;研究结束时6根仍在位正常工作。在3333个导管日(住院1471天和居家护理1862天)期间,6根导管因机械并发症(意外移位、渗漏、继发迁移)被拔除,14根因疑似或确诊感染被拔除。我们得出结论,麻醉医生经皮非血管造影插入Hickman导管可将技术成本降至最低,且至少与外科或放射学技术一样有效。临床上重要并发症的发生率是可以接受的。